[
  {
    "ts": "2026-02-08T22:31:03+00:00",
    "headline": "Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump",
    "summary": "Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer's drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis. Drugs Performance Biogen on Friday said fiscal 2025 revenue from growth products increased 19% year-over-year and offset the year-over-year revenue decline from multiple sclerosis products, exclu",
    "url": "https://finance.yahoo.com/news/biogen-hits-52-week-high-223103496.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "2ca664be-809e-34e2-9ca0-c82b123fd90c",
      "content": {
        "id": "2ca664be-809e-34e2-9ca0-c82b123fd90c",
        "contentType": "STORY",
        "title": "Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump",
        "description": "",
        "summary": "Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer's drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis. Drugs Performance Biogen on Friday said fiscal 2025 revenue from growth products increased 19% year-over-year and offset the year-over-year revenue decline from multiple sclerosis products, exclu",
        "pubDate": "2026-02-08T22:31:03Z",
        "displayTime": "2026-02-08T22:31:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/21bf2ba5092feb2ff1244849b2574405",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/et17ZYLuJGfwfOzY9tT2Mg--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/21bf2ba5092feb2ff1244849b2574405.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yhVfPK3gMQoxFpAIaHCbvw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/21bf2ba5092feb2ff1244849b2574405.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-hits-52-week-high-223103496.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-hits-52-week-high-223103496.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "ESAIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]